Skip to main content
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. — Investor Relations & Filings

Ticker · NAMS ISIN · NL00150012K9 LEI · 984500B6549TF6E14D36 US Professional, scientific and technical activities
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-05-02 Director's Dealing
Country NL Netherlands
Listing US NAMS

About NewAmsterdam Pharma Co N.V.

https://ir.newamsterdampharma.com/

NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases where currently approved treatments have not been sufficiently successful or well-tolerated. The company's lead product candidate is obicetrapib, an oral, low-dose, once-daily CETP inhibitor. It is being investigated as a therapy to lower low-density lipoprotein cholesterol (LDL-C) as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. The company aims to address the unmet need for a potent, cost-effective, and convenient LDL-lowering treatment. In addition to its dyslipidemia program, the company also explores treatments for other metabolic disorders.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-05-02 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, which is used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It includes detailed information about the meeting agenda, voting items, director nominations, executive compensation, and corporate governance matters. The document explicitly states it is a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934 and is related to the solicitation of proxies for the 2025 Annual General Meeting of shareholders. It is not the actual annual report or financial statements but rather the materials sent to shareholders to provide information and request votes for the meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is a full proxy statement, not a brief announcement or a report publication announcement.
2025-04-28 English
4
Director's Dealing
2025-04-21 English
4
Director's Dealing
2025-04-17 English
4
Director's Dealing
2025-04-17 English
3
Director's Dealing
2025-04-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.